Upadacitinib (Rinvoq®). HTA ID: 23013

Assessment Status Rapid Review Complete
HTA ID 23013
Drug Upadacitinib
Brand Rinvoq®
Indication Upadacitinib (Rinvoq®) is indicated for the treatment of adult patients with moderately to severely active Crohn’s Disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.
Assessment Process
Rapid review commissioned 03/03/2023
Rapid review completed 21/04/2023
Rapid review outcome A full HTA is not recommended. The NCPE recommends that upadacitinib not be considered for reimbursement at the submitted price*.

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.